Form 144 ImmunoGen, Inc. Filed by: Wingrove Theresa

Go back to Form 144 ImmunoGen, Inc. Filed by: Wingrove Theresa

Immunogen (IMGN) shares surge on news of takeover by AbbVie (ABBV)

November 30, 2023 9:09 AM EST

AbbVie (NYSE: ABBV) announced Thursday that it will acquire Immunogen (NASDAQ: IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.

The transaction values ImmunoGen at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.

Elahere... More